Gilead data lends insight into transforming HIV prevention landscape
European Pharmaceutical Review
NOVEMBER 13, 2024
New clinical trial findings show that twice-yearly lenacapavir for HIV pre-exposure prophylaxis (PrEP) had high efficacy and safety in a diverse group of participants. This data provides the first in-depth insight into full results of Gilead Sciences pivotal Phase III PURPOSE 2 trial.
Let's personalize your content